

Annual Results 2023



Ghent (Belgium), 19 September 2024, 6:00 a.m.; **bonyf NV (Mnemonic: MLBON)**, the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products and a leader in dental care innovation, presents its 2023 financial statements, approved by its Board of Directors and audited by its Statutory Auditors.

Balance and profit and loss sheet

(EUR)	31/12/2023	31/12/2022
Assets		
Fixed assets	3,000,000.00	4,000,000.00
IV. Financial fixed assets	3,000,000.00	4,000,000.00
A. Participating interests in affiliated enterprises	3,000,000.00	4,000,000.00
Current assets	92,858.95	170,599.95
VI. Stocks and contracts in progress	37,331.61	23,811.50
A.4. Goods purchased for resale	37,331.61	23,811.50
VII. Amounts receivable within one year	44,686.66	146,034.28
A. Trade debtors	34,985.39	129,816.99
B. Other amounts receivable	9,701.27	16,217.29
IX. Cash at bank and in hand	9,958.61	393.08
Cash at bank and in hand	9,958.61	393.08
X. Accruals and deferred income	882.07	361.09
Accruals and deferred charges	882.07	361.09
TOTAL ASSETS	3,092,858.95	4,170,599.95

(EUR)	31/12/2023	31/12/2022
Liabilities		
Equity	2,680,922.78	3,725,628.16
I. Capital	7,063,200.00	7,063,200.00
IV. Reserves	7,340.49	7,340.49
A. Other reserves not available	955.03	955.03
Other	955.03	955.03
D. Available reserves	6,385.46	6,385.46
V. Profit (Loss) brought forward (-)	-4,389,617.71	-3,344,912.33
Debts	411,936.17	444,971.79
IX. Amounts payable within one year	410,311.17	394,510.07
B. Financial debts	75,000.00	0.00
C. Trade debts	299,565.12	364,657.65
E.1. Taxes	10,538.53	11,592.00
E.2. Remunerations and social security	12,366.84	16,219.74
F. Other debts	12,840.68	2,040.68
X. Accruals and deferred income	1,625.00	50,461.72
Total liabilities	3,092,858.95	4,170,599.95

(EUR)	31/12/2023	31/12/2022
Profit and loss account		
Operating income and charges		
Turnover	309,374.55	277,397.63
A. Goods for resale, raw materials and consumables	124,404.47	138,541.34
Gross profit/loss (-)	184,970.08	138,856.29
Services and other goods	158,555.58	128,807.99
Gross margin	26,414.50	10,048.30
Remunerations, social security and pensions	55,859.32	56,061.16
Depreciation and amortisations	-140.87	50,034.99
Other operating charges	10,590.14	221,462.56
Operating profit/loss	-39,894.09	-317,510.41
Financial charges		
Recurring financial charges	4,811.29	352.69
Non-recurring financial charges	1,000,000.00	3,000,200.00
Profit/loss from recurrent operations (-)	-1,044,705.38	-3,318,063.10
Profit/loss before taxes (-)	-1,044,705.38	-3,318,063.10
Profit/loss to be appropriated (-)	-1,044,705.38	-3,318,063.10

(EUR)	31/12/2023	31/12/2022
Appropriation account	0.00	0.00
A. Profit/loss to be appropriated (-)	-4,389,617.71	-3,344,912.33
1. Profits/losses to be appropriated	-1,044,705.38	-3,318,063.10
2. Accumulated results of the preceding period	-3,344,912.33	-26,849.23
D. Results to be carried forward	4,389,617.71	3,344,912.33
2. Accumulated losses	4,389,617.71	3,344,912.33
TO BE APPROPRIATED THIS FINANCIAL YEAR	0.00	0.00

bonyf's strengths

- Products with patented formulations
- Produced in Switzerland compliant with stringent international quality regulations
- Proven clinical efficacy
- Commercial presence in 37 countries
- Prospects for solid growth and rapid profitability
- A fast-growing oral and dental care market



About bonyf

Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.

bonyf
 Jean-Pierre Bogaert
 investor@bonyf.com